Supplementary Table S4 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
<p>RNA-Seq DEG and GSEA</p>
Збережено в:
Схожі ресурси
Схожі ресурси
-
Supplementary Table S5 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
за авторством: Andrés Elía (15055031)
Опубліковано: (2025) -
Supplementary Table S6 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
за авторством: Andrés Elía (15055031)
Опубліковано: (2025) -
Supplementary Table S7 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
за авторством: Andrés Elía (15055031)
Опубліковано: (2025) -
Supplementary Table S8 from Beneficial Effects of Mifepristone Treatment in Patients with Breast Cancer Selected by the Progesterone Receptor Isoform Ratio: Results from the MIPRA Trial
за авторством: Andrés Elía (15055031)
Опубліковано: (2025) -
Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
за авторством: Nigel Bundred (15046233)
Опубліковано: (2025)